Skip to main content
BMC Infectious Diseases logoLink to BMC Infectious Diseases
. 2020 Jun 29;20:453. doi: 10.1186/s12879-020-05186-1

Biofilm formation, antimicrobial susceptibility and virulence genes of Uropathogenic Escherichia coli isolated from clinical isolates in Uganda

Paul Katongole 1,2,, Fatuma Nalubega 1, Najjuka Christine Florence 1, Benon Asiimwe 1, Irene Andia 3
PMCID: PMC7325280  PMID: 32600258

Abstract

Introduction

Uropathogenic E. coli is the leading cause of Urinary tract infections (UTIs), contributing to 80–90% of all community-acquired and 30–50% of all hospital-acquired UTIs. Biofilm forming Uropathogenic E. coli are associated with persistent and chronic inflammation leading to complicated and or recurrent UTIs. Biofilms provide an environment for poor antibiotic penetration and horizontal transfer of virulence genes which favors the development of Multidrug-resistant organisms (MDRO). Understanding biofilm formation and antimicrobial resistance determinants of Uropathogenic E. coli strains will provide insight into the development of treatment options for biofilm-associated UTIs. The aim of this study was to determine the biofilm forming capability, presence of virulence genes and antimicrobial susceptibility pattern of Uropathogenic E. coli isolates in Uganda.

Methods

This was a cross-sectional study carried in the Clinical Microbiology and Molecular biology laboratories at the Department of Medical Microbiology, Makerere University College of Health Sciences. We randomly selected 200 Uropathogenic E. coli clinical isolates among the stored isolates collected between January 2018 and December 2018 that had significant bacteriuria (> 105 CFU). All isolates were subjected to biofilm detection using the Congo Red Agar method and Antimicrobial susceptibility testing was performed using the Kirby disk diffusion method. The isolates were later subjected PCR for the detection of Urovirulence genes namely; Pap, Fim, Sfa, Afa, Hly and Cnf, using commercially designed primers.

Results

In this study, 62.5% (125/200) were positive biofilm formers and 78% (156/200) of these were multi-drug resistant (MDR). The isolates were most resistant to Trimethoprim sulphamethoxazole and Amoxicillin (93%) followed by gentamycin (87%) and the least was imipenem (0.5%). Fim was the most prevalent Urovirulence gene (53.5%) followed by Pap (21%), Sfa (13%), Afa (8%), Cnf (5.5%) and Hyl (0%).

Conclusions

We demonstrate a high prevalence of biofilm-forming Uropathogenic E. coli strains that are highly associated with the MDR phenotype. We recommend routine surveillance of antimicrobial resistance and biofilm formation to understand the antibiotics suitable in the management of biofilm-associated UTIs.

Keywords: Biofilms, Uropathogenic E. coli, Virulence genes, Antimicrobial resistance

Background

Urinary tract infections (UTIs) are one of the leading causes of morbidity affecting 150 million people each year worldwide [1]. E.coli is the most predominant pathogen causing over 80–90% of community-acquired and 30–50% of hospital-acquired UTIs [2]. The ability of Uropathogenic E.coli (UPEC) to invade, grow, ascend and persist in the uroepithelium is dependent on the ability to form biofilms and utilize different virulence factors [3]. These factors however are also countered by the hosts defenses such as urinary flow, expression of cytokines e.g. IL-8, Uro-epithelial defensin peptides such as Tamm-Horsfall protein (THP) and low molecular weight oligosaccharides. Hence the pathogenesis of UTIs relies on the balance between bacterial and host factors [4]. Biofilms represent an assemblage of microbial cells that is irreversibly associated with a surface and enclosed in a matrix of primarily polysaccharide material [5]. Biofilms provide a survival strategy to the bacteria by positioning them to effectively use the available nutrients and prevent access to antimicrobial agents, antibodies and white blood cells [6]. They have also been found to harbor a large number of antibiotic inactivating enzymes such as beta-lactamases hence creating an island of antimicrobial resistance [7].

UPEC strains encode a number of virulence genes that are associated with severe or recurrent UTIs, among these include; P fimbriae (pap), type1-fimbriae (fim-H), afimbrial-adhesin1 (afa1), S-fimbriae (sfa), hemolysin (hly), cytotoxic-necrotizing-factor (cnf1), aerobactin among others [8]. These help the organism to colonize the host surfaces, avoid and or subvert host defense mechanisms, injure and or invade host cells and tissues and incite a noxious inflammatory response hence leading to clinical disease [9]. Biofilm forming bacteria produce matrix composed of proteins, extracellular DNA and polysaccharides, these provide several benefits to the bacterial communities including; protection against immune cells, adhesion (facilitated by bacterial adhesins) and structure [10].

Several studies have demonstrated antimicrobial resistance among UPEC with increasing trends to the most commonly used antibiotics such as ciprofloxacin, trimethoprim-sulphamethoxazole among others [11, 12]. These antimicrobial resistance patterns tend to differ from one geographical region to another [13]. Timely and appropriate treatment is crucial in the management of UTIs; however, this should be based on evidence from regional antimicrobial susceptibility results, knowledge of the virulence genes and biofilm formation [14, 15]. Understanding the link between biofilm formation, presence of virulence genes and antimicrobial resistance distribution in UPEC strains is key in designing effective strategies and measures for prevention and management of UTIs especially severe, recurrent and complicated UTIs [14]. In this study, our goal was to determine the biofilm forming capability, presence of virulence genes and antimicrobial susceptibility pattern of UPEC clinical isolates in Uganda.

Methods

Bacterial strains and detection of Uropathogenic E. coli virulence genes

This was a cross-sectional study carried out from January 2019 to April 2019 at the Department of Medical Microbiology, Makerere University College of health sciences. A total of 200 E. coli isolates (collected and stored January to December 2018) that had been recovered from urine samples of patients with UTIs at Mulago National referral hospital outpatient. The isolates were from pure culture, identified and confirmed biochemically using standard laboratory SOPs. The DNA extraction was carried out using boiling lysis method as described by Reischl et al 2000 [16].

We used commercially designed primers for Pap, Fim, Sfa, Afa, Hly, and Cnf genes adapted from a study by Ruike Zhao et al 2015 [17]. The conditions and oligonucleotide sequences are as shown in Table 1. The amplified PCR products were visualized by 1.5% ethidium bromide staining after gel electrophoresis. The amplification of virulence genes was carried out in a Thermal Cycler (Eppendorf Master Cycler) under the following PCR conditions; denaturation at 94 °C for 2 min, followed by 30 cycles of denaturation at 94 °C for 60 s, annealing at 63 °C for 30 s, and extension at 72 °C for 90 s, with a final extension at 72 °C for 5 min. Strain J96 was used as positive control for Pap, Fim, Sfa, Hly, and Cnf sequences and strain K10 was used as positive control for Afa. Distilled water is used as negative control.

Table 1.

Oligonucleotide primers used for amplification of virulence genes among UPEC isolates

Primer name Oligonucleotide sequence (5′-3′) Sizes (bp) Gene
PapC-F GACGGCACTGCTGCAGGGTGTGGCG 328 papC
Pap-C-R ATATCCTTTCTGCAGGGATGCAATA
Fim-H-F TGTACTGCTGATGGGCTGGTC 564 fimH
Fim-H-R GGGTAGTCCGGCAGAGTAACG
Sfa-F CTCCGGAGAACTGGGTGCATCTTAC 410 Sfa
Sfa-R CGGAGGAGTAATTACAAACCTGGCA
Afa-F GCTGGGCAGCAAACTGATAACTCTC 750 Afa
Afa-R CATCAAGCTGTTTGTTCGTCCGCCG
HlyA-F AACAAGGATAAGCACTGTTCTGGCT 1177 hlyA
HlyA-R ACCATATAAGCGGTCATTCCCGTCA
Cnf1-F AAGATGGAGTTTCCTATGCAGGAG 498 cnf1
Cnf1-R TGGAGTTTCCTATGCAGGAG

Primers and sequences adapted from Ruike Zhao et al 2015

Detection of biofilm formation and antimicrobial susceptibility testing

For all E. coli isolates, biofilm formation was detected by Congo red agar method (CRA) as described by Freeman et al 1989 [18]. CRA medium was prepared by mixing brain heart infusion broth (Oxoid, UK) 37 g/L, sucrose 50 g/L, agar No. 1 (Oxoid, UK) 10 g/L and Congo red indicator (Oxoid, UK) 8 g/L. The Congo red stain was prepared as a concentrated aqueous solution and autoclaved (121 °C for 15 min) separately from the other medium constituents [18]. Congo red stain was later added to the autoclaved brain heart infusion agar with sucrose at 55 °C. CRA plates were later inoculated with test organisms and incubated at 37 °C for 24 h aerobically. Black colonies with a dry crystalline consistency indicated biofilm production whereas no-biofilm formation was identified as red or pink crystalline colonies. E. coli ATCC 25922 was used as positive control and Staphylococcus aureus ATCC 25932 as negative control for the CRA method.

Antimicrobial Susceptibility testing was performed using Kirby Bauer Disk diffusion method on Mueller Hinton agar according to the Clinical Laboratory Standard Institute (CLSI) 2014. Antibiotics tested for included; ampicillin10μg, cefuroxime 30μg, amoxicillin-clavulanic acid 20/10μg, gentamycin10μg, trimethoprim-sulphamethoxazole 1.25/23.5μg, chloramphenicol 5μg, ciprofloxacin 5μg, ceftriaxone 30μg, ceftazidime 30μg, meropenem 10ug, nalidixic acid 30μg, and nitrofurantoin 300μg. E. coli ATCC 25922 was used as positive control for the antimicrobial susceptibility testing.

Statistical analysis

The data was cleaned, double-checked and exported to STATA version 14 for statistical analysis. The Chi-square test was used to evaluate the correlations between variables. P- values of correlations less than 0.05 were considered statistically significant.

Ethical considerations

The study obtained approval from the Research and Ethics committee of the School of Biomedical Sciences, College of Health Sciences Makerere University (SBS-HDREC-515) and the Uganda National Council of Science and Technology.

Results

Out of 200 E. coli clinical isolates, 125 (62.5%) were able to produce biofilm. All isolates that produced dark crystalline colonies on CRA were considered for positive biofilm formation while those that produced red or pink colonies were considered no biofilm formation as shown in Fig. 1.

Fig. 1.

Fig. 1

Congo Red Agar plates showing biofilm and none-biofilm forming UPEC isolates

Among all the E. coli isolates antimicrobial susceptibility pattern varied with resistance with amoxicillin and co-trimoxazole being the highest (93%) followed by, gentamycin (87%), cefuroxime (84%), Nalidixic acid (79%), Amoxicillin clavulanic acid (62.5%), Ciprofloxacin (62%), ceftriaxone (55%),Ceftazidime (54%), chloramphenicol (28%), Nitrofurantoin (25.5%) and Imipenem (0.5%) Fig. 2.

Fig. 2.

Fig. 2

Percentage resistance of Uropathogenic E.coli Isolates (N = 200) to different antibiotics

Out of the 200 E. coli isolates, 156 (78%) were MDR (multi-drug resistant) i.e. resistance to more than two different antibiotic classes. Biofilm forming E. coli isolates were more resistant than the non-biofilm formers with 64% being MDR as compared to 36% among the non-biofilm forming E. coli as shown in Table 2 below. The likelihood of biofilm positive UPEC isolates to be MDR was statistically significant with a p-value of < 0.05 (within a confidence interval of 95%).

Table 2.

Multi-drug resistance among biofilm forming and non-biofilm forming UPEC isolates

Biofilm status MDR phenotype, n (%)
Biofilm formation 100 (64%)
No -Biofilm formation 56 (36%)

We carried out PCR detection of virulence genes and in this study the prevalence of fimH, Pap, Sfa, Afa, Hly and Cnf genes in Uropathogenic E. coli was; 53.5, 21, 13, 8%, 0 and 5.5% respectively (Fig. 3).

Fig. 3.

Fig. 3

Percentage frequency of Uropathogenic E.coli virulence genes

Biofilm formers had more adhesin genes (Fim, Pap, Sfa and Afa) than the non-biofilm formers with Fim being the most predominant virulence gene as shown in Fig. 4.

Fig. 4.

Fig. 4

Frequency of virulence genes among Biofilm and None Biofilm forming Uropathogenic E.coli isolates

Biofilm production was not significantly associated with the expression of any of the virulence genes.

Discussion

Biofilm forming bacteria are a common cause of recurrent, and complicated UTIs which are normally associated with MDR bacteria [1]. Understanding the pathogenesis and factors associated with biofilm formation is key to the development of new therapies [19]. In this study we sought to determine the biofilm forming capability, presence of virulence genes and antimicrobial susceptibility pattern of UPEC clinical isolates in Uganda.

Among 200 E. coli isolates subjected to biofilm production, the majority of the isolates,125 (62.5%) were biofilm formers on Congo Red Agar (CRA). This was similar to many previous studies [2022]. In this study we carried out antibiotic susceptibility pattern on all UPEC isolates in their planktonic state. The biofilm-forming isolates showed maximum resistance to Ampicillin and Cotrimoxazole (93%) followed by Gentamycin (87%), Cefuroxime (84%) and Nalidixic Acid (79%). Though resistance to different antibiotics was generally high, biofilm forming organisms were more MDR (64%) compared to non-biofilm formers and this was statistically significant with a p-value of < 0.05. Our findings are in agreement with the suggest that suggest biofilms to be associated with increased resistance to antibiotics [2325].

Previous studies have also indicated that biofilm-forming bacteria tend to exhibit higher resistance than planktonic cells due to the tough polymeric matrix that impends antibiotic penetration [26].

In this study, biofilm-forming organisms showed marked resistance to most commonly used antibiotics such as Ciprofloxacin, Ceftriaxone, and Gentamycin. This was also similar in a study by Neupane et al [12]. These findings underscore the need to regulate the use of antimicrobials and institutionalization of antimicrobial stewardship programs in hospitals to limit the spread of resistant microorganisms [27]. In Uganda there is no regulation of use of antibiotics with patients having access to over the counter prescriptions, this has been one of the major drivers of antibiotic resistance in the communities [28].

In the present study the prevalence of Fim, Pap, Sfa, Afa, Hly and Cnf genes in UPEC were determined and the results showed that among biofilm producers, Fim was the most prevalent Urovirulence gene followed by Pap, Sfa, Afa and Cnf. This was similar to other studies [29, 30]. In our study biofilm production was not associated with any of the virulence genes or resistance to any particular antibiotic. This was however different from other studies. A study by Manuela et al. reported that biofilm production was significantly associated with fluoroquinolone resistance [30]. In another similar study by Zamani et al it was found out that biofilm-producing UPEC were significantly associated with Fim gene [31].

Conclusions

This study demonstrated a high tendency among the UPEC isolates to form a biofilm. The biofilm-forming organisms were more MDR, produced more virulence genes compared to the non-biofilm forming organisms. Therefore, knowledge of biofilm formation, virulence factors and their antibiotic susceptibility pattern is key to guide the management of patients with biofilm associated infections.

Supplementary information

Additional file 1. (33.7KB, xlsx)

Acknowledgements

Not applicable.

Abbreviations

CLSI

Clinical and laboratory standards institute

DNA

Deoxyribose nucleic acid

MDR

Multi drug resistance

PCR

Polymerase chain reaction

SOPs

Standard Operating procedures

UPEC

Uropathogenic E. coli

Authors’ contributions

PK performed all the experiments, designed and implemented the study; FN, participated in designing the study and laboratory experiments, CFN, BB, and IA guided in the study design and implementation. The authors helped writing, read and approved the final manuscript.

Funding

This work was supported in part by the DELTAS Africa Initiative [grant # 107743/Z/15/Z]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA), and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant no. 107743) and the UK Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its supplementary information files]. DOI; 10.6084/m9.figshare.11321936 Fig share.

Ethics approval and consent to participate

The study obtained approval from the Research and Ethics committee of the School of Biomedical Sciences, College of Health Sciences Makerere University (SBS-HDREC-515). The Ethics Committee waived the requirement for informed consent as the investigated isolates were obtained from clinical specimens referred to the diagnostic laboratory as part of routine care

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s12879-020-05186-1.

References

  • 1.Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269. doi: 10.1038/nrmicro3432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ejrnæs K. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan Med Bull. 2011;58(4):B4187. [PubMed] [Google Scholar]
  • 3.Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front Microbiol. 2017;8:1566. doi: 10.3389/fmicb.2017.01566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Spencer JD, Schwaderer AL, Becknell B, Watson J, Hains DS. The innate immune response during urinary tract infection and pyelonephritis. Pediatr Nephrol [Internet] 2013;29(7):1139–1149. doi: 10.1007/s00467-013-2513-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002;8(9):881. doi: 10.3201/eid0809.020063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Nandakumar V, Chittaranjan S, Kurian VM, Doble M. Characteristics of bacterial biofilm associated with implant material in clinical practice. Polym J. 2013;45(2):137. doi: 10.1038/pj.2012.130. [DOI] [Google Scholar]
  • 7.Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433. doi: 10.1128/MMBR.00016-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sarowska J, Futoma-Koloch B, Jama-Kmiecik A, Frej-Madrzak M, Ksiazczyk M, Bugla-Ploskonska G, et al. Virulence factors, prevalence and potential transmission of extraintestinal pathogenic Escherichia coli isolated from different sources: recent reports. Gut Pathog. 2019;11(1):10. doi: 10.1186/s13099-019-0290-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lüthje P, Brauner A. Virulence factors of uropathogenic E. coli and their interaction with the host. In: Advances in microbial physiology: Elsevier; 2014. p. 337–72. 10.1016/bs.ampbs.2014.08.006, https://pubmed.ncbi.nlm.nih.gov/25476769/. [DOI] [PubMed]
  • 10.Limoli DH, Jones CJ, Wozniak DJ. Bacterial extracellular polysaccharides in biofilm formation and function. Microbiol Spectr. 2015;3(3). Available from: 10.1128/microbiolspec.MB-0011-2014. [DOI] [PMC free article] [PubMed]
  • 11.Ali I, Rafaque Z, Ahmed S, Malik S, Dasti JI. Prevalence of multi-drug resistant uropathogenic Escherichia coli in Potohar region of Pakistan. Asian Pac J Trop Biomed. 2016;6(1):60–66. doi: 10.1016/j.apjtb.2015.09.022. [DOI] [Google Scholar]
  • 12.Neupane S, Pant ND, Khatiwada S, Chaudhary R, Banjara MR. Correlation between biofilm formation and resistance toward different commonly used antibiotics along with extended spectrum beta lactamase production in uropathogenic Escherichia coli isolated from the patients suspected of urinary tract infections visit. Antimicrob Resist Infect Control. 2016;5(1):5. doi: 10.1186/s13756-016-0104-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Parveen S, Lukasik J, Scott TM, Tamplin ML, Portier KM, Sheperd S, et al. Geographical variation in antibiotic resistance profiles of Escherichia coli isolated from swine, poultry, beef and dairy cattle farm water retention ponds in Florida 1. J Appl Microbiol. 2006;100(1):50–57. doi: 10.1111/j.1365-2672.2005.02773.x. [DOI] [PubMed] [Google Scholar]
  • 14.Donelli G, Vuotto C. Biofilm-based infections in long-term care facilities. Future Microbiol. 2014;9(2):175–188. doi: 10.2217/fmb.13.149. [DOI] [PubMed] [Google Scholar]
  • 15.Karam MRA, Habibi M, Bouzari S. Relationships between virulence factors and antimicrobial resistance among Escherichia coli isolated from urinary tract infections and commensal isolates in Tehran, Iran. Osong public Heal Res Perspect. 2018;9(5):217. doi: 10.24171/j.phrp.2018.9.5.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ahmed OB, Asghar AH, Elhassan MM. Comparison of three DNA extraction methods for polymerase chain reaction (PCR) analysis of bacterial genomic DNA. African J Microbiol Res. 2014;8(6):598–602. doi: 10.5897/AJMR2013.6459. [DOI] [Google Scholar]
  • 17.Zhao R, Shi J, Shen Y, Li Y, Han Q, Zhang X, et al. Phylogenetic distribution of virulence genes among ESBL-producing uropathogenic Escherichia coli isolated from long-term hospitalized patients. J Clin diagnostic Res JCDR. 2015;9(7):DC01. doi: 10.7860/JCDR/2015/13234.6157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Jain A, Agarwal A. Biofilm production, a marker of pathogenic potential of colonizing and commensal staphylococci. J Microbiol Methods. 2009;76(1):88–92. doi: 10.1016/j.mimet.2008.09.017. [DOI] [PubMed] [Google Scholar]
  • 19.Römling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med. 2012;272(6):541–561. doi: 10.1111/joim.12004. [DOI] [PubMed] [Google Scholar]
  • 20.Subramanian P, Shanmugam N, Sivaraman U, Kumar S, Selvaraj S. Antiobiotic resistance pattern of biofilm-forming uropathogens isolated from catheterised patients in Pondicherry, India. Australas Med J. 2012;5(7):344. doi: 10.4066/AMJ.2012.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Dash D, Sarangi G, Patro P, Chayani N. Study of biofilm production in Escherichia coli causing urinary tract infection and its correlation with antimicrobial resistance. J Acad Clin Microbiol. 2018;20(2):88. doi: 10.4103/jacm.jacm_35_17. [DOI] [Google Scholar]
  • 22.Sudheendra KR, Basavaraj PV. Analysis of antibiotic sensitivity profile of biofilm-forming uropathogenic Escherichia coli. J Nat Sci Biol Med. 2018;9(2):175. doi: 10.4103/jnsbm.JNSBM_209_17. [DOI] [Google Scholar]
  • 23.Reisner A, Krogfelt KA, Klein BM, Zechner EL, Molin S. In vitro biofilm formation of commensal and pathogenic Escherichia coli strains: impact of environmental and genetic factors. J Bacteriol. 2006;188(10):3572–3581. doi: 10.1128/JB.188.10.3572-3581.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ong C-LY, Ulett GC, Mabbett AN, Beatson SA, Webb RI, Monaghan W, et al. Identification of type 3 fimbriae in uropathogenic Escherichia coli reveals a role in biofilm formation. J Bacteriol. 2008;190(3):1054–1063. doi: 10.1128/JB.01523-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ponnusamy P, Natarajan V, Sevanan M. In vitro biofilm formation by uropathogenic Escherichia coli and their antimicrobial susceptibility pattern. Asian Pac J Trop Med. 2012;5(3):210–213. doi: 10.1016/S1995-7645(12)60026-1. [DOI] [PubMed] [Google Scholar]
  • 26.Singh S, Singh SK, Chowdhury I, Singh R. Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents. Open Microbiol J. 2017;11:53. doi: 10.2174/1874285801711010053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001. doi: 10.1016/S1473-3099(17)30325-0. [DOI] [PubMed] [Google Scholar]
  • 28.Namuwenge JM, Mwesige OG, Mukanga N. Over-the-counter suboptimal dispensing of antibiotics in Uganda. J Multidiscip Healthc. 2013;303Available from:. 10.2147/JMDH.S49075. [DOI] [PMC free article] [PubMed]
  • 29.Ahmed N, Zeshan B, Naveed M, Afzal M, Mohamed M. Antibiotic resistance profile in relation to virulence genes fimH, hlyA and usp of uropathogenic E. coli isolates in Lahore, Pakistan. Trop Biomed. 2019;36(2):559–568. [PubMed] [Google Scholar]
  • 30.Stephenson SAM, Brown PD. Distribution of virulence determinants among antimicrobial-resistant and antimicrobial-susceptible Escherichia coli implicated in urinary tract infections. Indian J Med Microbiol. 2016;34(4):448. doi: 10.4103/0255-0857.195354. [DOI] [PubMed] [Google Scholar]
  • 31.Zamani H, Salehzadeh A. Biofilm formation in uropathogenic Escherichia coli: association with adhesion factor genes. Turkish J Med Sci. 2018;48(1):162–167. doi: 10.3906/sag-1707-3. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 1. (33.7KB, xlsx)

Data Availability Statement

All data generated or analyzed during this study are included in this published article [and its supplementary information files]. DOI; 10.6084/m9.figshare.11321936 Fig share.


Articles from BMC Infectious Diseases are provided here courtesy of BMC

RESOURCES